JOHN G MORIKIS, a director at $JNJ, bought 1,250 shares of the company on 11-26-2025 for an estimated $257,687. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their holdings of this class of stock by approximately 209.0%. Following this trade, they now own 1,848 shares of this class of $JNJ stock.
$JNJ Insider Trading Activity
$JNJ insiders have traded $JNJ stock on the open market 6 times in the past 6 months. Of those trades, 1 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $JNJ stock by insiders over the last 6 months:
- JOAQUIN DUATO (CEO and Chairman of the Board) sold 125,824 shares for an estimated $22,548,654
- JENNIFER L TAUBERT (EVP, WWC. Innovative Medicine) sold 56,471 shares for an estimated $10,040,882
- JOHN C REED (EVP, Innovative Medicine, R&D) has made 0 purchases and 2 sales selling 40,858 shares for an estimated $7,315,622.
- JOSEPH J WOLK (Exec VP, CFO) sold 16,820 shares for an estimated $2,975,570
- JOHN G MORIKIS purchased 1,250 shares for an estimated $257,687
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$JNJ Hedge Fund Activity
We have seen 1,953 institutional investors add shares of $JNJ stock to their portfolio, and 2,024 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 12,124,049 shares (+61.6%) to their portfolio in Q3 2025, for an estimated $2,248,041,165
- GQG PARTNERS LLC added 5,988,242 shares (+12137.4%) to their portfolio in Q3 2025, for an estimated $1,110,339,831
- GEODE CAPITAL MANAGEMENT, LLC removed 4,394,021 shares (-7.2%) from their portfolio in Q3 2025, for an estimated $814,739,373
- BLACKROCK, INC. added 3,411,739 shares (+1.7%) to their portfolio in Q3 2025, for an estimated $632,604,645
- FLOSSBACH VON STORCH SE removed 3,347,823 shares (-52.8%) from their portfolio in Q3 2025, for an estimated $620,753,340
- CAPITAL INTERNATIONAL INVESTORS added 3,266,354 shares (+545.6%) to their portfolio in Q3 2025, for an estimated $605,647,358
- PACER ADVISORS, INC. removed 2,632,092 shares (-84.2%) from their portfolio in Q3 2025, for an estimated $488,042,498
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$JNJ Congressional Stock Trading
Members of Congress have traded $JNJ stock 15 times in the past 6 months. Of those trades, 4 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $JNJ stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 6 times. They made 3 purchases worth up to $45,000 on 10/30, 08/04, 06/17 and 3 sales worth up to $45,000 on 10/31, 10/30, 06/24.
- REPRESENTATIVE JARED MOSKOWITZ has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 10/10.
- REPRESENTATIVE VAL T. HOYLE sold up to $15,000 on 09/23.
- REPRESENTATIVE KELLY MORRISON sold up to $15,000 on 08/19.
- REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 08/14.
- REPRESENTATIVE THOMAS H. KEAN, JR. sold up to $50,000 on 07/31.
- REPRESENTATIVE SCOTT FRANKLIN sold up to $50,000 on 06/16.
- REPRESENTATIVE PETE SESSIONS sold up to $50,000 on 06/12.
- REPRESENTATIVE LLOYD DOGGETT purchased up to $15,000 on 06/10.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$JNJ Analyst Ratings
Wall Street analysts have issued reports on $JNJ in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 10/14/2025
- Citigroup issued a "Buy" rating on 10/07/2025
- Wells Fargo issued a "Overweight" rating on 10/03/2025
- RBC Capital issued a "Outperform" rating on 07/17/2025
To track analyst ratings and price targets for $JNJ, check out Quiver Quantitative's $JNJ forecast page.
$JNJ Price Targets
Multiple analysts have issued price targets for $JNJ recently. We have seen 14 analysts offer price targets for $JNJ in the last 6 months, with a median target of $202.0.
Here are some recent targets:
- Ilya Zubkov from Freedom Capital Markets set a target price of $190.0 on 10/22/2025
- Terence Flynn from Morgan Stanley set a target price of $190.0 on 10/15/2025
- Tim Anderson from B of A Securities set a target price of $204.0 on 10/15/2025
- Jayson Bedford from Raymond James set a target price of $209.0 on 10/15/2025
- Rick Wise from Stifel set a target price of $190.0 on 10/15/2025
- Joanne Wuensch from Citigroup set a target price of $215.0 on 10/15/2025
- Danielle Antalffy from UBS set a target price of $214.0 on 10/14/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
